The Group Average Absolute Chemotherapy Benefit is the potential reduction in distant recurrence risk across all ages within this range of Recurrence Score results when chemotherapy is added.*
Quantitative ER, PR, and HER2 scores by RT-PCR, specific to your patient.
START REPORT GUIDE
Estimated Chemotherapy Benefit
The NSABP B-20 study randomized patients to treatment with TAM alone or TAM + CT and validated that Recurrence Score results are predictive of chemotherapy benefit.
The TAILORx study is a prospective trial in which patients with Recurrence Score results between 11-25 were randomly assigned ET alone or ET + CT. Treatment with ET alone was found to be non-inferior to ET + CT across patients of all ages. An exploratory subgroup analysis in patients ≤50 years of age showed a small chemotherapy benefit beginning at Recurrence Score results of 16, and the benefit increases as the Recurrence Score result increases.
Details regarding the data used to report distant recurrence risk and absolute chemotherapy benefit, including clinical trial characteristics, sample sizes, and confidence intervals.
The Recurrence Score result is based on the quantitative analysis of the expression of 21 genes within the patient’s tumor sample
Prognosis
Patient’s individualized risk of distant recurrence when treated with endocrine therapy alone*
*based on TransATAC node-positive clinical trial population
Prediction
The Group Average Absolute Chemotherapy Benefit is the potential reduction in distant recurrence risk across all ages within this range of Recurrence Score results when chemotherapy is added*
*based on SWOG 8814 node-positive clinical trial population
Real World Patient Outcomes
This table provides real world outcomes for patients treated without the addition of chemotherapy*
Quantitative ER, PR, and HER2 scores by RT-PCR, specific to your patient.
START REPORT GUIDE
Estimated Chemotherapy Benefit
The SWOG 8814 study randomized node-positive patients by treatment type (TAM or TAM +CT) and determined the 5-year risk of distant recurrence or mortality based on each patient’s Recurrence Score result.
Details regarding the data used to report distant recurrence risk and absolute chemotherapy benefit, including clinical trial characteristics, sample sizes, and confidence intervals.
